Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Molecular subtypes and the (in vitro) response of glioblastoma to temozolomide.

BJC reports·2026
Same author

Machine learning, whole genome sequencing, and Mendelian randomization support a role of CRP on COVID-19 severity.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Molecular subtypes and the (in vitro) response of glioblastoma to temozolomide.

BJC reports·2026
Same author

A Polypharmacology-Driven Approach to Alzheimer's Disease and Tauopathies: Rational Design, Synthesis and Characterization of Amino-Pyrazole-Based Multikinase (GSK-3β/FYN-α/DYRK1A) Inhibitors.

Journal of medicinal chemistry·2026
Same author

From comprehensive geriatric assessment to rapid bedside screening: comparing MPI and BRASS in predicting hospital outcomes in older adults - the S. Giovanni-Addolorata Hospital-SIGOT GRACE study.

BMC geriatrics·2026
Same author

Multi-parametric profiling of plasma-derived extracellular vesicles reveals a disease-associated molecular signature supporting a liquid biopsy approach in myelofibrosis.

Molecular medicine (Cambridge, Mass.)·2026

Related Experiment Video

Updated: Jul 5, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K

GPCR Inhibition in Treating Lymphoma.

Marilia Barreca1, Virginia Spanò1, Maria V Raimondi1

  • 1Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.

ACS Medicinal Chemistry Letters
|January 19, 2024
PubMed
Summary

G protein-coupled receptors (GPCRs) are implicated in cancer, particularly lymphomas. This review focuses on synthetic strategies for GPCR inhibitors, especially CXCR4 inhibitors, for cancer treatment.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.7K

Related Experiment Videos

Last Updated: Jul 5, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.1K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.7K

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • G protein-coupled receptors (GPCRs) are crucial cell surface receptors regulating physiological functions.
  • Aberrant GPCR signaling pathways are frequently observed in various cancers, driving proliferation, angiogenesis, and metastasis.
  • GPCR alterations are increasingly recognized in different lymphoma subtypes.

Purpose of the Study:

  • To review synthetic strategies for developing GPCR inhibitors.
  • To highlight CXCR4 inhibitors as a significant class for cancer therapy, particularly lymphomas.

Main Methods:

  • Literature review of synthetic strategies for GPCR inhibitors.
  • Focus on CXCR4 inhibitors and their relevance in cancer and lymphoma treatment.

Main Results:

  • GPCRs play a significant role in cancer development and progression.
  • CXCR4 inhibitors are a promising therapeutic avenue, with many in market or preclinical development for these diseases.

Conclusions:

  • Targeting GPCRs, especially CXCR4, offers a viable strategy for cancer and lymphoma treatment.
  • Continued research into synthetic strategies for GPCR inhibitors is essential for advancing oncology therapeutics.